FoxM1 expression is significantly associated with cisplatin-based chemotherapy resistance and poor prognosis in advanced non-small cell lung cancer patients

Lung Cancer

Volumn 79, Issue 2, 2013, Pages 173-179

  Wang, Yu ^a   Wen, Li ^b   Zhao, Shu hua ^a   Ai, Zhen hua ^a   Guo, Jun zhao ^a   Liu, Wen chao ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Chemoresistance; Cisplatin; FoxM1; Non small cell lung cancer; Prognosis; Survival

Indexed keywords

CISPLATIN; DOCETAXEL; GEMCITABINE; NAVELBINE; SMALL INTERFERING RNA; THIOSTREPTON; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXM1; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CANCER PATIENT; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER STAGING; CELL DEATH; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG RESISTANCE; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; TREATMENT RESPONSE; WESTERN BLOTTING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL MOVEMENT; CISPLATIN; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; PROPORTIONAL HAZARDS MODELS; RNA, MESSENGER; TAXOIDS; VINBLASTINE;

EID: 84872137211     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.10.019     Document Type: Article

References (46)

1. Hofman P., Mauer A., Vokes E. Lung cancer. Lancet 2000, 355:479-485.
2. Kamangar F., Dores G.M., Anderson W.F. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006, 24:2137-2150.
3. Wood A.J.J., Spira A., Ettinger D.S. Multidisciplinary management of lung cancer. N Engl J Med 2004, 350:379-392.
4. Raez L., Lilenbaum R. Chemotherapy for advanced non-small-cell lung cancer. Clin Adv Hematol Oncol 2004, 2:173-178.
5. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346:92-98.
6. Ohe Y., Ohashi Y., Kubota K., Tamura T., Nakagawa K., Negoro S., et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 2007, 18:317-323.
7. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
8. Ardizzoni A., Boni L., Tiseo M., Fossella F.V., Schiller J.H., Paesmans M., et al. Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 2007, 99:847-857.
9. Kashkin K., Musatkina E., Komelkov A., Tonevitsky E., Sakharov D., Vinogradova T., et al. Genes potentially associated with cisplatin resistance of lung cancer cells. Dokl Biochem Biophys 2011, 438:147-150.
10. Chang X., Ravi R., Pham V., Bedi A., Chatterjee A., Sidransky D. Adenylate kinase 3 sensitizes cells to cigarette smoke condensate vapor induced cisplatin resistance. PloS ONE 2011, 6:e20806.
11. Rosell R., Lord R.V.N., Taron M., Reguart N. DNA repair and cisplatin resistance in non-small-cell lung cancer. Lung Cancer 2002, 38:217-227.
12. Laoukili J., Kooistra M.R.H., Brás A., Kauw J., Kerkhoven R.M., Morrison A., et al. FoxM1 is required for execution of the mitotic programme and chromosome stability. Nat Cell Biol 2005, 7:126-136.
13. Laoukili J., Stahl M., Medema R.H. FoxM1: at the crossroads of ageing and cancer. Biochim Biophys Acta 2007, 1775:92-102.
14. Leung T.W.C., Lin S.S.W., Tsang A.C.C., Tong C.S.W., Ching J.C.Y., Leung W.Y., et al. Over-expression of FoxM1 stimulates cyclin B1 expression. FEBS Lett 2001, 507:59-66.
15. Wang X., Kiyokawa H., Dennewitz M.B., Costa R.H. The Forkhead box M1b transcription factor is essential for hepatocyte DNA replication and mitosis during mouse liver regeneration. Proc Natl Acad Sci USA 2002, 99:16881-16886.
16. Wonsey D.R., Follettie M.T. Loss of the Forkhead transcription factor FoxM1 causes centrosome amplification and mitotic catastrophe. Cancer Res 2005, 65:5181-5189.
17. Kalin T.V., Ustiyan V., Kalinichenko V.V. Multiple faces of FoxM1 transcription factor. Cell Cycle 2011, 10:396-405.
18. Douard R., Moutereau S., Pernet P., Chimingqi M., Allory Y., Manivet P., et al. Sonic hedgehog-dependent proliferation in a series of patients with colorectal cancer. Surgery 2006, 139:665-670.
19. Teh M.T., Wong S.T., Neill G.W., Ghali L.R., Philpott M.P., Quinn A.G. FOXM1 is a downstream target of Gli1 in basal cell carcinomas. Cancer Res 2002, 62:4773-4780.
20. Kalin T.V., Wang I., Ackerson T.J., Major M.L., Detrisac C.J., Kalinichenko V.V., et al. Increased levels of the FoxM1 transcription factor accelerate development and progression of prostate carcinomas in both TRAMP and LADY transgenic mice. Cancer Res 2006, 66:1712-1720.
21. Liu M., Dai B., Kang S.H., Ban K., Huang F.J., Lang F.F., et al. FoxM1B is overexpressed in human glioblastomas and critically regulates the tumorigenicity of glioma cells. Cancer Res 2006, 66:3593-3620.
22. Kim I.M., Ackerson T., Ramakrishna S., Tretiakova M., Wang I., Kalin T.V., et al. The Forkhead box M1 transcription factor stimulates the proliferation of tumor cells during development of lung cancer. Cancer Res 2006, 66:2153-2161.
23. Kalinichenko V.V., Major M.L., Wang X., Petrovic V., Kuechle J., Yoder H.M., et al. FoxM1B transcription factor is essential for development of hepatocellular carcinomas and is negatively regulated by the p19ARF tumor suppressor. Genes Dev 2004, 18:830-850.
24. Wang Z., Banerjee S., Kong D., Li Y., Sarkar F.H. Down-regulation of Forkhead box M1 transcription factor leads to the inhibition of invasion and angiogenesis of pancreatic cancer cells. Cancer Res 2007, 67:8293-8300.
25. Millour J., Lam E. FOXM1 is a transcriptional target of ERα and has a critical role in breast cancer endocrine sensitivity and resistance. Oncogene 2010, 29:2983-2995.
26. Hui M.K.C., Chan K.W., Luk J.M., Lee N.P., Chung Y., Cheung L.C.M., et al. Cytoplasmic Forkhead box M1 (FoxM1) in esophageal squamous cell carcinoma significantly correlates with pathological disease stage. World J Surg 2012, 36:90-97.
27. Lok G.T.M., Chan D.W., Liu V.W.S., Hui W.W.Y., Leung T.H.Y., Yao K., et al. Aberrant activation of ERK/FOXM1 signaling cascade triggers the cell migration/invasion in ovarian cancer cells. PloS ONE 2011, 6:e23790.
28. Bektas N., Haaf A., Veeck J., Wild P., Lüscher-Firzlaff J., Hartmann A., et al. Tight correlation between expression of the Forkhead transcription factor FOXM1 and HER2 in human breast cancer. BMC Cancer 2008, 8:42.
29. Li Q., Zhang N., Jia Z., Le X., Dai B., Wei D., et al. Critical role and regulation of transcription factor FoxM1 in human gastric cancer angiogenesis and progression. Cancer Res 2009, 69:3501-3509.
30. Xia L., Fan D., Wu K. 382 upregulated FOXM1 expression induced by hepatitis B virus X protein promotes tumor metastasis and indicates poor prognosis in hepatitis B virus-related hepatocellular carcinoma. J Hepatol 2012, 57:600-612.
31. Chu X.Y., Zhu Z.M., Chen L.B., Wang J.H., Su Q.S., Yang J.R., et al. FOXM1 expression correlates with tumor invasion and a poor prognosis of colorectal cancer. Acta Histochem 2012, 114:755-762.
32. Xia J.T., Wang H., Liang L.J., Peng B.G., Wu Z.F., Chen L.Z., et al. Overexpression of FOXM1 is associated with poor prognosis and clinicopathologic stage of pancreatic ductal adenocarcinoma. Pancreas 2012, 41:629-635.
33. Sun H., Teng M., Liu J., Jin D., Wu J., Yan D., et al. FOXM1 expression predicts the prognosis in hepatocellular carcinoma patients after orthotopic liver transplantation combined with the Milan criteria. Cancer Lett 2011, 306:214-222.
34. Priller M., Pöschl J., Abrão L., von Bueren A.O., Cho Y.J., Rutkowski S., et al. Expression of FoxM1 is required for the proliferation of medulloblastoma cells and indicates worse survival of patients. Clin Cancer Res 2011, 17:6791-6801.
35. Xu N., Zhang X., Wang X., Ge H., Garfield D., Yang P., et al. FoxM1 mediated resistance to gefitinib in non-smallcell lung cancer cells. Acta Pharmacol Sin 2012, 33:675-681.
36. Kwok J.M.M., Peck B., Monteiro L.J., Schwenen H.D.C., Millour J., Coombes R.C., et al. FOXM1 confers acquired cisplatin resistance in breast cancer cells. Mol Cancer Res 2010, 8:24-34.
37. Carr J.R., Park H.J., Wang Z., Kiefer M.M., Raychaudhuri P. FoxM1 mediates resistance to herceptin and paclitaxel. Cancer Res 2010, 70:5054-5063.
38. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000, 92:205-216.
39. Bhat U.G., Halasi M., Gartel A.L. Thiazole antibiotics target FoxM1 and induce apoptosis in human cancer cells. PloS ONE 2009, 4:e5592.
40. Kwok J.M.M., Myatt S.S., Marson C.M., Coombes R.C., Constantinidou D., Lam E.W.F. Thiostrepton selectively targets breast cancer cells through inhibition of Forkhead box M1 expression. Mol Cancer Ther 2008, 7:2022-2032.
41. Korver W., Roose J., Clevers H. The winged-helix transcription factor trident is expressed in cycling cells. Nucleic Acids Res 1997, 25:1715-1719.
42. Ye H., Kelly T.F., Samadani U., Lim L., Rubio S., Overdier D.G., et al. Hepatocyte nuclear factor 3/fork head homolog 11 is expressed in proliferating epithelial and mesenchymal cells of embryonic and adult tissues. Mol Cell Biol 1997, 17:1626-1641.
43. Kalinina O.A., Kalinin S.A., Polack E.W., Mikaelian I., Panda S., Costa R.H., et al. Sustained hepatic expression of FoxM1B in transgenic mice has minimal effects on hepatocellular carcinoma development but increases cell proliferation rates in preneoplastic and early neoplastic lesions. Oncogene 2003, 22:6266-6276.
44. Pilarsky C., Wenzig M., Specht T., Saeger H.D., Grützmann R. Identification and validation of commonly overexpressed genes in solid tumors by comparison of microarray data. Neoplasia (New York, NY) 2004, 6:744-750.
45. Uddin S., Ahmed M., Hussain A., Abubaker J., Al-Sanea N., AbdulJabbar A., et al. Genome-wide expression analysis of Middle Eastern colorectal cancer reveals FOXM1 as a novel target for cancer therapy. Am J Pathol 2011, 178:537-547.
46. Okabe H., Satoh S., Kato T., Kitahara O., Yanagawa R., Yamaoka Y., et al. Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray. Cancer Res 2001, 61:2129-2137.